| Patents for A61P 21 - Drugs for disorders of the muscular or neuromuscular system (23,287) |
|---|
| 06/21/2001 | WO2001044472A1 Tnfr/opg-like molecules and uses thereof |
| 06/21/2001 | WO2001044468A1 Novel protein and gene |
| 06/21/2001 | WO2001044445A2 Human lyases and associated proteins |
| 06/21/2001 | WO2001044268A1 Halogenated sulphamate-, phosphonate-, thiophosphonate-, sulphonate- and sulphonamide- compounds as inhibitors of steroid sulphatase |
| 06/21/2001 | WO2001044248A1 Imidazopyrimidinyl and imidazopyridinyl derivatives |
| 06/21/2001 | WO2001044243A2 Novel heteroaryl-diazabicycloalkanes |
| 06/21/2001 | WO2001044217A1 Aminothiazole inhibitors of cyclin dependent kinases |
| 06/21/2001 | WO2001043775A2 Hydroxide-releasing agents as skin permeation enhancers |
| 06/21/2001 | WO2001043773A1 Tnf-alpha antagonist and lfa-1 antagonist for treating lfa-1 or tnf-alpha mediated disorder |
| 06/21/2001 | WO2001043691A2 Fragments and antagonists of heat shock protein 60 |
| 06/21/2001 | CA2394538A1 Aminothiazole inhibitors of cyclin dependent kinases |
| 06/21/2001 | CA2394536A1 Tnfr/opg-like molecules and uses thereof |
| 06/21/2001 | CA2394504A1 Fragments and antagonists of heat shock protein 60 |
| 06/21/2001 | CA2394466A1 Polypeptides and nucleic acids encoding same |
| 06/21/2001 | CA2394269A1 Methods and compositions for identifying morphogenic protein analogs using morphogenic protein responsive inhibitory elements |
| 06/21/2001 | CA2393762A1 Hydroxide-releasing agents as skin permeation enhancers |
| 06/21/2001 | CA2392992A1 Imidazopyrimidinyl and imidazopyridinyl derivatives |
| 06/21/2001 | CA2390689A1 Human lyases and associated proteins |
| 06/20/2001 | EP1108047A1 Targeted adenovirus vectors for delivery of heterologous genes |
| 06/20/2001 | EP1108039A2 Elongase genes and uses thereof |
| 06/20/2001 | EP1107978A1 Secreted proteins and polynucleotides encoding them |
| 06/20/2001 | EP1107973A1 Novel compounds |
| 06/20/2001 | EP1107788A1 Scrp-5: secreted cysteine rich protein-5 |
| 06/20/2001 | EP1107775A1 Composition containing pyrrolizidine-alkaloid-free petasites |
| 06/20/2001 | EP1107753A1 Multivalent agonists, partial agonists, inverse agonists and antagonists of the 5ht2 receptors |
| 06/20/2001 | EP1107744A2 Use of substance p antagonists for the treatment of chronic fatigue syndrome and/or fibromyalgia and use of nk-1 receptor antagonists for the treatment of chronic fatigue syndrome |
| 06/20/2001 | CN1300280A Process for the preparation of (R)-& alpha, -(2,3-dimethoxyp-henyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol |
| 06/20/2001 | CN1300187A Dietary supplement derived from fermented milks for the prevention of osteoporosis |
| 06/20/2001 | CN1067262C Medicine for treating muscular tremor |
| 06/19/2001 | US6248901 Heterocyclic vinyl ethers |
| 06/19/2001 | US6248754 Psychological disorders |
| 06/19/2001 | US6248594 Kinesin-like motor protein |
| 06/19/2001 | US6248363 Improved delivery of hydrophilic or hydrophobic pharmaceutical active ingredients, such as drugs, nutraceuticals, cosmeceuticals and diagnostic agents |
| 06/19/2001 | CA2190973C Novel 4,6-diarylpyrimidine derivatives and salts thereof |
| 06/14/2001 | WO2001042459A1 Apoptosis inhibitory polypeptide, gene and polynucleotide encoding it and compositions containing the same |
| 06/14/2001 | WO2001042305A1 Interleukin-1 receptor antagonist-like molecules and uses thereof |
| 06/14/2001 | WO2001042288A2 G-protein coupled receptors |
| 06/14/2001 | WO2001042241A1 Substituted pyridazines having cytokine inhibitory activity |
| 06/14/2001 | WO2001042238A1 Heterocyclic derivatives |
| 06/14/2001 | WO2001042222A1 Polymorphic crystalline forms of celecoxib |
| 06/14/2001 | WO2001042221A1 Solid-state form of celecoxib having enhanced bioavailability |
| 06/14/2001 | WO2001042216A2 Caspase inhibitors and uses thereof |
| 06/14/2001 | WO2001041762A2 Valdecoxib compositions |
| 06/14/2001 | WO2001041761A2 Valdecoxib compositions |
| 06/14/2001 | WO2001041760A2 Cyclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect |
| 06/14/2001 | WO2001041743A1 New (aminopropyl)methylphosphinic acids |
| 06/14/2001 | WO2001041536A2 Solid-state form of celecoxib having enhanced bioavailability |
| 06/14/2001 | WO2001003720A3 Promotion or inhibition of angiogenesis and cardiovascularization by tumor necrosis factor ligand/receptor homologs |
| 06/14/2001 | CA2733434A1 Caspase inhibitors and uses thereof |
| 06/14/2001 | CA2393661A1 Interleukin-1 receptor antagonist-like molecules and uses thereof |
| 06/14/2001 | CA2393510A1 New (aminopropyl)methylphosphinic acids |
| 06/14/2001 | CA2392961A1 G-protein coupled receptors |
| 06/14/2001 | CA2392584A1 Substituted pyridazines having cytokine inhibitory activity |
| 06/14/2001 | CA2362815A1 Cyclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect |
| 06/14/2001 | CA2362675A1 Polymorphic crystalline forms of celecoxib |
| 06/13/2001 | EP1106614A1 5-Membered heteroaryl substituted 1,4-dihydropyridine compounds as bradykinin antagonists |
| 06/13/2001 | EP1105734A2 Homer interacting proteins |
| 06/13/2001 | EP1105478A1 Extracellular adhesive proteins, exadh1 and exadh2 |
| 06/13/2001 | EP1105459A1 Transgenic nonhuman mammal and uses thereof to identify compounds useful for improving long-term memory |
| 06/13/2001 | EP1105370A1 Novel aryl sulphonamides and analogues |
| 06/13/2001 | CN1299361A Hypnotic beta-carboline derivatives, process for their prepn. and their use as medicinal products |
| 06/13/2001 | CN1299346A Ureas and carbamates of N-heterocyclic carboxylic acids and carboxylic acid isosteres |
| 06/13/2001 | CN1299283A Composition comprising L-carnitine or an alkanoyl L-carnitine and NADH and/or NADPH |
| 06/13/2001 | CN1298717A Process for preparing Tibetan medicines |
| 06/12/2001 | US6245778 1,6-naphthyridine anti-convulsants |
| 06/10/2001 | CA2327925A1 5-membered heteroaryl substituted 1,4-dihydropyridine compounds as bradykinin antagonists |
| 06/07/2001 | WO2001040521A2 Nucleic acids containing single nucleotide polymorphisms and methods of use thereof |
| 06/07/2001 | WO2001040316A1 6-mercapto-cyclodextrin derivatives: reversal agents for drug-induced neuromuscular block |
| 06/07/2001 | WO2001040249A1 Four disulfide core domain-containing (fdcd) polynucleotides, polypeptides, and antibodies |
| 06/07/2001 | WO2001040231A1 Heterocyclic dihydropyrimidines as potassium channel inhibitors |
| 06/07/2001 | WO2001040216A1 Heterocyclo-alkylsulfonyl pyrazole derivatives as anti-inflammatory/analgesic agents |
| 06/07/2001 | WO2001040187A2 Compound having effect of promoting neuron differentiation |
| 06/07/2001 | WO2001040185A1 Compounds, compositions, and methods for stimulating neuronal growth and elongation |
| 06/07/2001 | WO2001039776A1 Combination of an ergoline and riluzole for preventing and treating motor neuron diseases |
| 06/07/2001 | WO2000074703B1 Therapeutic agent comprising a botulinum neurotoxin |
| 06/07/2001 | US20010002998 Over-coated chewing gum formulations including tableted center |
| 06/07/2001 | CA2392948A1 Nucleic acids containing single nucleotide polymorphisms and methods of use thereof |
| 06/07/2001 | CA2392931A1 Heterocyclo-alkylsulfonyl pyrazole derivatives as anti-inflammatory/analgesic agents |
| 06/07/2001 | CA2392693A1 Four disulfide core domain-containing (fdcd) polynucleotides, polypeptides, and antibodies |
| 06/07/2001 | CA2389368A1 Compounds, compositions, and methods for stimulating neuronal growth and elongation |
| 06/07/2001 | CA2388239A1 Neuroprotective agents and methods related thereto |
| 06/06/2001 | EP1104758A1 Acetylene derivatives as anti-inflammatory/analgesic agents |
| 06/06/2001 | EP1104404A1 Substituted isoquinoline derivatives and their use as anticonvulsants |
| 06/06/2001 | EP1104309A2 Protected one-vial formulation for nucleic acid molecules, methods of making the same by in-line mixing, and related products and methods |
| 06/06/2001 | CN1066626C Traumatic paraplegia pills or capsules |
| 06/05/2001 | US6242479 Use of γ-tocopherol and its oxidative metabolite LLU-α in the treatment of disease |
| 06/05/2001 | US6242438 3-Azetidinylalkylpiperidines or -pyrrolidines as tachykinin antagonists |
| 05/31/2001 | WO2001038548A2 Vectors capable of immortalizing non-dividing cells and cells immortalized with said vectors |
| 05/31/2001 | WO2001038503A2 Novel human protein kinases and protein kinase-like enzymes |
| 05/31/2001 | WO2001038486A2 Kunitz-type protease inhibitor polynucleotides, polypeptides, and antibodies |
| 05/31/2001 | WO2001038361A1 Modified adenovirus fibre and uses |
| 05/31/2001 | WO2001038326A2 Imidazo-pyridine derivatives as ligands for gaba receptors |
| 05/31/2001 | WO2001038325A1 5-membered n-heterocyclic compounds with hypoglycemic and hypolipidemic activity |
| 05/31/2001 | WO2001038320A1 Vitamin d analogues |
| 05/31/2001 | WO2001038316A2 Sulfonyl oxazole amines and their use as 5-ht6 receptor ligands |
| 05/31/2001 | WO2001038314A1 3,4-dihydro-(1h)quinazolin-2-one compounds as csbp/p38 kinase inhibitors |
| 05/31/2001 | WO2001038313A1 3,4-DIHYDRO-(1H)QUINAZOLIN-2-ONE COMPOUNDS AS CSBP/p39 kINASE INHIBITORS |
| 05/31/2001 | WO2001038311A2 Pyrimidine derivatives as selective inhibitors of cox-2 |
| 05/31/2001 | WO2001038304A1 Heterocyclic ketone and thioester compounds and uses |
| 05/31/2001 | WO2001037868A1 Assays and therapies for latent viral infection |